Co-administration of Nanowired Oxiracetam and Neprilysin with Monoclonal Antibodies to Amyloid Beta Peptide and p-Tau Thwarted Exacerbation of Brain Pathology in Concussive Head Injury at Hot Environment

Summary: This study found that extreme temperatures worsen brain injuries from concussions, particularly in military personnel. It also discovered that delivering oxiracetam alongside specific antibodies and enzymes significantly improved brain protection under hot conditions following such injuries.

Link: PubMed

Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study

Summary: The study found that (S)-oxiracetam, a drug being developed for dementia, was safe and well-tolerated in healthy Chinese volunteers, with most adverse events being mild or moderate. The drug showed favorable pharmacokinetic profiles, such as rapid absorption and dose-proportional exposure, supporting further research on its efficacy.

Link: PubMed

Oxiracetam in dementia: a double-blind, placebo-controlled study

Summary: The study evaluated the effectiveness and tolerability of oxiracetam compared to a placebo in patients with various types of dementia over 12 weeks, using a range of neuropsychological tests and a quality of life scale. Results indicated oxiracetam significantly improved quality of life and some cognitive functions, despite a few patients experiencing minor side effects.

Link: PubMed

Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study

Summary: This study evaluated the effectiveness and tolerability of the drug oxiracetam compared to a placebo in patients with various types of dementia over 12 weeks, involving 289 patients who completed the analysis. The results showed that oxiracetam significantly improved symptoms based on several dementia-related scales, with minor side effects being reported similarly in both the oxiracetam and placebo groups.

Link: PubMed

Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia

Summary: The study tested Oxiracetam, a nootropic, on 34 patients with multi-infarct dementia (MID) and 39 patients with primary degenerative dementia (PDD), finding significant improvements in word fluency for both patient groups. However, while patients with PDD showed improvement in global symptoms, their ability to perform daily activities declined.

Link: PubMed

Effects of Oxiracetam and Physical Activity in Preventing Post-Stroke Cognitive Decline: A Randomized Controlled Trial

Summary: This study found that oxiracetam did not significantly prevent cognitive decline in post-stroke patients, but adherence to physical activity guidelines helped maintain cognitive function. Although there were overall improvements in memory and fluency in both groups, only the exercise group showed significant improvements in certain quality-of-life measures.

Link: ScienceDirect

Using HPLC to analyze (S)-oxiracetam and four related substances in the bulk drug of (S)-oxiracetam

Summary: Researchers have developed a precise method using high-performance liquid chromatography (HPLC) to analyze (S)-oxiracetam and its impurities in the bulk drug form, showing high accuracy and reliability. This method can be used for quality control and stability monitoring of (S)-oxiracetam in pharmaceutical settings.

Link: ScienceDirect

Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke

Summary: This study found that combining bone marrow stromal cells (BMSCs) with the drug oxiracetam significantly improved neurological function and reduced cell death in rats after a stroke compared to using either treatment alone. Enhanced expression of B-cell lymphoma 2 (Bcl-2) and reduced apoptosis may explain the improved outcomes.

Link: ScienceDirect

Determination and correlation of solubility and solution thermodynamics of oxiracetam in three (alcohol + water) binary solvents

Summary: The study investigated the solubility of racemic oxiracetam in three different alcohol-water mixtures and found that solubility increases with temperature but decreases with higher alcohol content. Various models were used to accurately describe the solubility data, and additional thermodynamic properties were derived to further understand its dissolution behavior.

Link: ScienceDirect

Pharmacokinetics of oxiracetam and its degraded substance (HOPAA) after oral and intravenous administration in rats

Summary: This study examined how the drug oxiracetam and its breakdown product HOPAA behave in rats when given orally or intravenously, using advanced measurement techniques. Results showed quick elimination of both substances in the bloodstream, found HOPAA to be non-toxic, and revealed that the oral bioavailability of oxiracetam was much lower than previously reported, highlighting the need for further research.

Link: ScienceDirect